Xinqiao Hospital of Chongqing

Clinical Update: Long-Term Follow up on...
May. 26, 2021

This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...

Trial Update: CRISPR-Edited Therapies for Sickle...
Mar. 24, 2021

This week’s clinical update looks at 3 clinical trials for the treatment of sickle cell disease (SCD), relapsed or refractory blood cancers and...

Xinqiao Hospital of Chongqing

T-Cell Acute Lymphoblastic Leukaemia, T-ALL, (ChiCTR1900025311)
Sponsors:
Xinqiao Hospital of Chongqing, Second Affiliated Hospital of the Army Medical University, Hematology Department
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Lymphoblastic Leukaemia and Lymphoma, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine